Autolus Therapeutics PLC expected to post a loss of 25 cents a share - Earnings Preview

Autolus Therapeutics

31/10/2023 14:33

* Autolus Therapeutics PLC  AUTL.OQ   AUTL.O  is expected
to show
a fall in quarterly revenue when it reports  results 
    * The London United Kingdom-based   company is expected to
report 
a 81.2% decrease in revenue to $446.29 thousand from $2.37
million a year ago, according to the mean estimate from 7
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Autolus
Therapeutics PLC
is for a loss of 25 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Autolus
Therapeutics PLC is $9​, above​ its last closing price of $2.72.
​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.21       -0.22      -0.26     Missed  -15.9
 Mar. 31 2023  -0.26       -0.27      -0.23     Beat    13.6
 Dec. 31 2022  -0.06       -0.27      -0.23     Beat    14.4​
 Sep. 30 2022  -0.49       -0.46      -0.47     Missed  -1
 ​​Jun.        -0.42       -0.42      -0.46     Missed  -9.5
 30 2022                                                
 Mar. 31 2022  -0.49       -0.48      -0.41     Beat    14.8​
 Dec. 31 2021  -0.53       -0.46      -0.51     Missed  -10.5
 Sep. 30 2021  -0.52       -0.51      -0.47     Beat    7
 This summary was machine generated October 31 at 14:33 GMT.  All
figures in US dollars  unless otherwise stated